Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 15/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zavolosotine SCHEMBL22976253 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29720042 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29720019 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29720029 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29720052 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL22976243 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL22976246 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL22976175 | 1.00 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29811252 | 0.99 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 | |
| Zavolosotine SCHEMBL29811260 | 0.99 | SSTR2 (0.38) | SSTR2CYP2C9CYP2C19SSTR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | claimed |
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | Crinetics Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | claimed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | claimed |
| WO-2022177974-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20220259175-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. | 2022-08-18 | — | — | US | claimed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| CN-114585614-A | Non-peptide somatostatin type 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | claimed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | claimed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | claimed |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885CYP2C9 4639/4885CYP2C19 3783/4885 |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885CYP2C9 4639/4885CYP2C19 3783/4885 |
| US-20220259175-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | SSTR5, SSTR3, SSTR4 | SSTR2 5/4885CYP2C9 4089/4885CYP2C19 2923/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885CYP2C9 4639/4885CYP2C19 3783/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885CYP2C9 4639/4885CYP2C19 3783/4885 |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | SSTR5, SSTR3, SSTR4 | SSTR2 5/4885CYP2C9 4089/4885CYP2C19 2923/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | SSTR2 4/4885CYP2C9 2278/4885CYP2C19 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.